Silexion Therapeutics Faces Delisting Notice
Ticker: SLXNW · Form: 8-K · Filed: Jul 21, 2025 · CIK: 2022416
Sentiment: bearish
Topics: delisting, listing-standards, sec-filing
Related Tickers: SLXN
TL;DR
SLXN got a delisting warning from NASDAQ, stock might be in trouble.
AI Summary
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on July 21, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, incorporated in the Cayman Islands, is based in Ramat-Gan, Israel, and its stock is traded on NASDAQ under the ticker SLXN.
Why It Matters
This filing indicates potential delisting from NASDAQ, which could significantly impact the liquidity and valuation of Silexion Therapeutics' stock.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued trading on a major exchange.
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- Biomotion Sciences (company) — Former company name
- NASDAQ (company) — Stock exchange
- July 21, 2025 (date) — Report date
- July 18, 2025 (date) — Earliest event reported
FAQ
What is the specific reason for Silexion Therapeutics' notice of delisting or failure to satisfy a continued listing rule?
The filing does not specify the exact reason for the delisting notice, only that it is a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing'.
When was Silexion Therapeutics previously known as Biomotion Sciences?
The company changed its name from Biomotion Sciences to Silexion Therapeutics Corp. on May 6, 2024.
On which stock exchange is Silexion Therapeutics Corp. listed?
Silexion Therapeutics Corp. is listed on NASDAQ.
What is the principal executive address of Silexion Therapeutics Corp.?
The principal executive address is 12 Abba Hillel Road, Ramat-Gan, Israel, 5250606.
What is the filing date of this 8-K report?
This 8-K report was filed on July 21, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 21, 2025 regarding Silexion Therapeutics Corp (SLXNW).